AI assistant
Edgewise Therapeutics, Inc. — Director's Dealing 2021
Oct 19, 2021
31829_dirs_2021-10-18_678fcd25-9699-44f1-9b74-84b35a70549d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-10-14
Reporting Person: Russell Alan J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-10-14 | Common Stock | S | 5749.00 | $18.18 | Disposed | 145275.00 | Direct |
| 2021-10-15 | Common Stock | S | 1307.00 | $18.1317 | Disposed | 143968.00 | Direct |
| 2021-10-15 | Common Stock | S | 126.00 | $18.00 | Disposed | 143842.00 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.
F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.